Recursion Pharmaceuticals Announces Board Transition as Founder Chris Gibson Declines Re-election

On April 28, 2026, Recursion Pharmaceuticals, Inc. announced that Christopher Gibson, Ph.D., the company's Co-Founder and Chair of the Board of Directors, will not stand for re-election as a Class II Director at the 2026 Annual Meeting of Stockholders. Dr. Gibson's current term is set to expire in June 2026. The company clarified that his decision to step down from the Board was not due to any disagreement regarding operations, policies, or practices. Dr. Gibson will continue to serve as Chair and participate in his assigned committees (Research and Development, Technology, and Corporate Social Responsibility) until the expiration of his term. Following his departure from the Board, he is expected to remain connected to the company in a strategic advisory capacity. The leadership transition follows the recent appointment of Najat Khan, Ph.D., as Chief Executive Officer and President. Dr. Gibson expressed confidence in the company's future under current leadership and its AI-powered drug discovery platform, the Recursion OS.